Journal of Periodontal and Implant Science

Korean Academy of Periodontology (대한치주과학회)
권호 표지
DOI QR코드

DOI QR Code

Enhancement of peri-implant bone formation via parathyroid hormone administration in a rat model at risk for medication-related osteonecrosis of the jaw

  • Park, Ji Young (Department of Dentistry, Graduate School, The Catholic University of Korea) ;
  • Heo, Hyun A (Department of Dentistry, College of Medicine, The Catholic University of Korea) ;
  • Park, Suhyun (Department of Dentistry, College of Medicine, The Catholic University of Korea) ;
  • Pyo, Sung Woon (Department of Dentistry, College of Medicine, The Catholic University of Korea)
  • Received : 2019.12.17
  • Accepted : 2020.02.18
  • Published : 2020.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Dental implant-associated medication-related osteonecrosis of the jaw has been frequently reported in patients administered bisphosphonates (BPs) to prevent osteoporosis. The aim of this study was to investigate the effect of intermittent administration of parathyroid hormone (PTH) on peri-implant bone in the maxillae of ovariectomized rats systemically administered BPs. Methods: Thirty 8-week-old female Sprague-Dawley rats were randomly divided into 3 groups. The OVX-ZP group included ovariectomized rats administered 60 ㎍/kg of zoledronate once a week for 6 weeks and 30 ㎍/kg PTH after implant installation. The OVX-Z group included ovariectomized rats administered 60 ㎍/kg of zoledronate once a week for 6 weeks and saline after implant installation, and the control group included rats that underwent a sham operation and were then administered saline. Rats were sacrificed 4 weeks after implant placement for histomorphometric and micro-computed tomography (CT) analyses. Results: The average bone area percentage was greater in the OVX-ZP group than in the OVX-Z group (53.4%±4.0% vs. 28.9%±9.5%, P=0.01). The bone-to-implant contact ratio was 50.8%±1.4% in the OVX-ZP group and 16.9%±2.4% in the OVX-Z group (P=0.012). The average bone volume ratio as shown on micro-CT was 31.3%±19.8% in the OVX-ZP group and 19.4%±9.3% in the OVX-Z group (P=0.045). The OVX-ZP and OVX-Z groups displayed similar trabecular thickness (0.06±0.004 mm vs. 0.06±0.002 mm) (P>0.05) and trabecular separation (0.21±0.02 mm vs. 0.29±0.13 mm) (P>0.05). However, the number of trabeculae in the OVX-ZP group was significantly higher than that in the OVX-Z group (4.3±1.33/㎣ vs. 2.2±0.19/㎣) (P=0.024). Conclusions: The present findings indicate that intermittently-administered PTH can promote peri-implant bone formation and suggest that PTH administration may aid in effective treatment for medication-related osteonecrosis of the jaw after dental implantation.

Keywords

References

  1. Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent 2013;61:33-8.
  2. Papapoulos SE. Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 2008;22:831-47. https://doi.org/10.1016/j.beem.2008.07.001
  3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  4. Ristow O, Gerngross C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, et al. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis? J Oral Maxillofac Surg 2014;72:903-10. https://doi.org/10.1016/j.joms.2013.11.005
  5. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
  6. Mucke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 2011;137:907-13. https://doi.org/10.1007/s00432-010-0953-1
  7. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010;18:449-60. https://doi.org/10.1007/s00520-009-0688-1
  8. Eckardt AM, Lemound J, Lindhorst D, Rana M, Gellrich NC. Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients: a challenging problem. Anticancer Res 2011;31:2313-8.
  9. Ikeda T, Kuraguchi J, Kogashiwa Y, Yokoi H, Satomi T, Kohno N. Successful treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) patients with sitafloxacin: new strategies for the treatment of BRONJ. Bone 2015;73:217-22. https://doi.org/10.1016/j.bone.2014.12.021
  10. Park JH, Kim JW, Kim SJ. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw? J Oral Maxillofac Surg 2017;75:1176-84. https://doi.org/10.1016/j.joms.2016.12.005
  11. Bedogni A, Bettini G, Totola A, Saia G, Nocini PF. Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg 2010;68:1662-6. https://doi.org/10.1016/j.joms.2010.02.037
  12. Tam Y, Kar K, Nowzari H, Cha HS, Ahn KM. Osteonecrosis of the jaw after implant surgery in patients treated with bisphosphonates--a presentation of six consecutive cases. Clin Implant Dent Relat Res 2014;16:751-61. https://doi.org/10.1111/cid.12048
  13. Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2014;72:1937.e1-8.
  14. Nisi M, La Ferla F, Karapetsa D, Gennai S, Miccoli M, Baggiani A, et al. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofac Surg 2015;44:586-91. https://doi.org/10.1016/j.ijom.2015.01.014
  15. Chadha GK, Ahmadieh A, Kumar S, Sedghizadeh PP. Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review. J Oral Implantol 2013;39:510-20. https://doi.org/10.1563/AAID-JOI-D-11-00234
  16. Javed F, Almas K. Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol 2010;81:479-84. https://doi.org/10.1902/jop.2009.090587
  17. Dayisoylu EH, Senel FC, Ungor C, Tosun E, Cankaya M, Ersoz S, et al. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. Int J Oral Maxillofac Surg 2013;42:1475-80. https://doi.org/10.1016/j.ijom.2013.05.001
  18. Ersan N, van Ruijven LJ, Bronckers AL, Olgac V, Ilguy D, Everts V. Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model. Dentomaxillofac Radiol 2014;43:20130144. https://doi.org/10.1259/dmfr.20130144
  19. Keskinruzgar A, Bozdag Z, Aras MH, Demir T, Yolcu U, Cetiner S. Histopathological effects of teriparatide in medication-related osteonecrosis of the jaw: an animal study. J Oral Maxillofac Surg 2016;74:68-78. https://doi.org/10.1016/j.joms.2015.07.005
  20. Doh RM, Park HJ, Rhee Y, Kim HS, Huh J, Park W. Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants. Implant Dent 2015;24:222-6. https://doi.org/10.1097/ID.0000000000000232
  21. Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010;363:2396-405. https://doi.org/10.1056/NEJMoa1005361
  22. Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007;40:1447-52. https://doi.org/10.1016/j.bone.2006.09.008
  23. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 2009;44:275-86. https://doi.org/10.1016/j.bone.2008.10.037
  24. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007;65:573-80. https://doi.org/10.1016/j.joms.2006.10.076
  25. Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis JR. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist 2010;30:77-82. https://doi.org/10.1111/j.1754-4505.2009.00128.x
  26. Sharma D, Hamlet S, Petcu E, Ivanovski S. Animal models for bisphosphonate-related osteonecrosis of the jaws--an appraisal. Oral Dis 2013;19:747-54. https://doi.org/10.1111/odi.12067
  27. Heo HA, Park SH, Jeon YS, Pyo SW. Enhancing effect of intermittent parathyroid hormone administration on bone formation after titanium implant placement in an ovariectomized rat maxilla. Implant Dent 2016;25:227-31. https://doi.org/10.1097/ID.0000000000000352
  28. Park S, Heo HA, Kim KW, Min JS, Pyo SW. Intermittent parathyroid hormone improves bone formation around titanium implants in osteoporotic rat maxillae. Int J Oral Maxillofac Implants 2017;32:204-9. https://doi.org/10.11607/jomi.5037
  29. Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015;44:568-85. https://doi.org/10.1016/j.ijom.2015.01.026
  30. Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010;68:790-6. https://doi.org/10.1016/j.joms.2009.09.017
  31. Kim JW, Baik J, Jeon JH. Dental implant treatment after healing of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in the same region: a case report. J Korean Assoc Oral Maxillofac Surg 2016;42:157-61. https://doi.org/10.5125/jkaoms.2016.42.3.157
  32. Cardemil C, Omar OM, Norlindh B, Wexell CL, Thomsen P. The effects of a systemic single dose of zoledronic acid on post-implantation bone remodelling and inflammation in an ovariectomised rat model. Biomaterials 2013;34:1546-61. https://doi.org/10.1016/j.biomaterials.2012.11.003
  33. Lopez-Jornet P, Camacho-Alonso F, Molina-Minano F, Gomez-Garcia F, Vicente-Ortega V. An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. J Oral Pathol Med 2010;39:697-702. https://doi.org/10.1111/j.1600-0714.2010.00927.x
  34. Jang HW, Kim JW, Cha IH. Development of animal model for Bisphosphonates-related osteonecrosis of the jaw (BRONJ). Maxillofac Plast Reconstr Surg 2015;37:18. https://doi.org/10.1186/s40902-015-0020-6
  35. Dikicier E, Karacayli U, Dikicier S, Gunaydin Y. Effect of systemic administered zoledronic acid on osseointegration of a titanium implant in ovariectomized rats. J Craniomaxillofac Surg 2014;42:1106-11. https://doi.org/10.1016/j.jcms.2014.01.039
  36. Yoshiga D, Yamashita Y, Nakamichi I, Tanaka T, Yamauchi K, Yamamoto N, et al. Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 2013;24:2365-9. https://doi.org/10.1007/s00198-013-2277-x
  37. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007;40:1434-46. https://doi.org/10.1016/j.bone.2007.03.017
  38. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003;144:2008-15. https://doi.org/10.1210/en.2002-221061
  39. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest 2008;38:798-803. https://doi.org/10.1111/j.1365-2362.2008.02033.x
  40. Hamada H, Matsuo A, Koizumi T, Satomi T, Chikazu D. A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. J Craniomaxillofac Surg 2014;42:924-9. https://doi.org/10.1016/j.jcms.2014.01.012
  41. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 1994;15:717-23. https://doi.org/10.1016/8756-3282(94)90322-0

Cited by

  1. Parathyroid Hormone 1 Receptor Signaling in Dental Mesenchymal Stem Cells: Basic and Clinical Implications vol.9, 2020, https://doi.org/10.3389/fcell.2021.654715